Log in
LON:HIK

Hikma Pharmaceuticals PLC (HIK.L) Share Forecast, Price & News

GBX 2,595
-37.00 (-1.41 %)
(As of 12/1/2020 08:08 AM ET)
Add
Compare
Today's Range
2,590
Now: GBX 2,595
2,632
50-Day Range
2,510
MA: GBX 2,612.53
2,695
52-Week Range
1,596
Now: GBX 2,595
2,768
Volume9,655 shs
Average Volume673,570 shs
Market Capitalization£5.98 billion
P/E Ratio12.29
Dividend Yield0.92%
BetaN/A
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops and manufactures oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Hikma Pharmaceuticals PLC (HIK.L) logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.4Community Rank: 2.8Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.25 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-73992760
Employees8,600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£2.29 billion
Cash FlowGBX 177.02 per share
Book ValueGBX 777 per share

Profitability

Miscellaneous

Market Cap£5.98 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableNot Optionable
GBX 2,595
-37.00 (-1.41 %)
(As of 12/1/2020 08:08 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HIK News and Ratings via Email

Sign-up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Hikma Pharmaceuticals PLC (HIK.L) (LON:HIK) Frequently Asked Questions

How has Hikma Pharmaceuticals PLC (HIK.L)'s stock price been impacted by Coronavirus?

Hikma Pharmaceuticals PLC (HIK.L)'s stock was trading at GBX 1,828.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HIK stock has increased by 42.6% and is now trading at GBX 2,608.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Hikma Pharmaceuticals PLC (HIK.L)?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals PLC (HIK.L) in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Hikma Pharmaceuticals PLC (HIK.L)
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Hikma Pharmaceuticals PLC (HIK.L)?

Wall Street analysts have given Hikma Pharmaceuticals PLC (HIK.L) a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Hikma Pharmaceuticals PLC (HIK.L) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Hikma Pharmaceuticals PLC (HIK.L)'s next earnings date?

Hikma Pharmaceuticals PLC (HIK.L) is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Hikma Pharmaceuticals PLC (HIK.L)
.

How often does Hikma Pharmaceuticals PLC (HIK.L) pay dividends? What is the dividend yield for Hikma Pharmaceuticals PLC (HIK.L)?

Hikma Pharmaceuticals PLC (HIK.L) declared a dividend on Friday, August 7th. Stockholders of record on Thursday, August 20th will be given a dividend of GBX 0.16 per share on Monday, September 21st. This represents a yield of 0.52%. The ex-dividend date is Thursday, August 20th. The official announcement can be seen at this link.
View Hikma Pharmaceuticals PLC (HIK.L)'s dividend history
.

What price target have analysts set for HIK?

8 analysts have issued 1 year price objectives for Hikma Pharmaceuticals PLC (HIK.L)'s stock. Their forecasts range from GBX 2,200 to GBX 2,860. On average, they expect Hikma Pharmaceuticals PLC (HIK.L)'s stock price to reach GBX 2,478.57 in the next twelve months. This suggests that the stock has a possible downside of 5.0%.
View analysts' price targets for Hikma Pharmaceuticals PLC (HIK.L)
.

Who are some of Hikma Pharmaceuticals PLC (HIK.L)'s key competitors?

What other stocks do shareholders of Hikma Pharmaceuticals PLC (HIK.L) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals PLC (HIK.L) investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil Co. (ATH.TO) (ATH), Gran Tierra Energy Inc. (GTE.TO) (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC).

Who are Hikma Pharmaceuticals PLC (HIK.L)'s key executives?

Hikma Pharmaceuticals PLC (HIK.L)'s management team includes the following people:
  • Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 63, Pay $3.05M)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 51, Pay $4.12M)
  • Mr. Mazen Samih Taleb Darwazah, Exec. Vice Chairman & Pres of MENA (Age 62, Pay $2.18M)
  • Mr. Khalid Waleed Hosny Al Nabilsi, Chief Financial Officer (Age 48)
  • Dr. Shahin Fesharaki, Chief Scientific Officer & Global Head of Research Devel.
  • Mr. Hussein Arkhagha, Chief Counsel
  • Mr. Bassam Wael Rushdi Kanaan, Exec. VP of Corp. Devel. and M&A (Age 55)
  • Ms. Susan Ringdal, Exec. VP of Strategic Planning & Global Affairs
  • Ms. Majda Labadi, Exec. VP of Organisational Devel.
  • Mr. Riad Mishlawi, Pres of Injectables

What is Hikma Pharmaceuticals PLC (HIK.L)'s stock symbol?

Hikma Pharmaceuticals PLC (HIK.L) trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How do I buy shares of Hikma Pharmaceuticals PLC (HIK.L)?

Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hikma Pharmaceuticals PLC (HIK.L)'s stock price today?

One share of HIK stock can currently be purchased for approximately GBX 2,608.

How big of a company is Hikma Pharmaceuticals PLC (HIK.L)?

Hikma Pharmaceuticals PLC (HIK.L) has a market capitalization of £6.01 billion and generates £2.29 billion in revenue each year. Hikma Pharmaceuticals PLC (HIK.L) employs 8,600 workers across the globe.

What is Hikma Pharmaceuticals PLC (HIK.L)'s official website?

The official website for Hikma Pharmaceuticals PLC (HIK.L) is www.hikma.com.

How can I contact Hikma Pharmaceuticals PLC (HIK.L)?

Hikma Pharmaceuticals PLC (HIK.L)'s mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.